Combination of retinoic acids (RAs) and interferons (IFNs) has synergistic apoptotic effects and is used in cancer treatment. However, the underlying mechanisms remain unknown. Here, we demonstrate that mitochondrial respiratory chain (MRC) plays an essential role in the IFN-b/RA-induced cancer cell death. We found that IFN-b/RA upregulates the expression of MRC complex subunits. Mitochondrial-nuclear translocation of these subunits was not observed, but overproduction of reactive oxygen species (ROS), which causes loss of mitochondrial function, was detected upon IFN-b/RA treatment. Knockdown of GRIM-19 (gene associated with retinoid-interferon-induced mortality-19) and NDUFS3 (NADH dehydrogenase (ubiquinone) Fe-S protein 3), two subunits of MRC complex I, by siRNA in two cancer cell lines conferred resistance to IFN-b/RA-induced apoptosis and reduced ROS production. In parallel, expression of late genes induced by IFN-b/RA that are directly involved in growth inhibition and cell death was also repressed in the knockdown cells. Our data suggest that the MRC regulates IFN-b/RA-induced cell death by modulating ROS production and late gene expression.
Interferons (IFNs) play leading roles in the host defense against viruses, bacteria, and parasites. 1 IFNs are also important negative growth factors that inhibit cell proliferation and induce apoptosis. 2 Three major classes of IFNs, including IFN-a, IFN-b, and IFN-g, have been identified. 3 Retinoic acids (RAs) are natural and synthetic derivatives of Vitamin A. Alltrans-retinoic acid and 9-cis-RA are active metabolites that bind and activate the nuclear receptors, all-trans-RA receptors (RARs) and retinoid X receptors (RXRs), and control expression of various genes. 4, 5 RAs inhibit proliferation and induce differentiation of cancer cells. 6, 7 Interestingly, RA and IFN potentiate each other to induce biological responses. Various combinations of RAs and IFNs have demonstrated synergistic effects by inhibiting proliferation and inducing differentiation, as well as apoptotic activity in cancer cell lines and in human hematologic and solid tumor models. 8, 9 However, the molecular basis of their effects is poorly understood.
GRIM-19 (genes associated with retinoid-IFN-induced mortality-19) was identified as an IFN-b-and RA-induced gene with proapoptotic nature in the breast cancer cell lines. 10 GRIM-19 was initially implicated as a nuclear protein, and its precise role in the IFN-b-and RA-induced tumor cell death was not clear. 10 Subsequently, the bovine GRIM-19 homolog was found to copurify with mitochondrial NADH:ubiquinone oxidoreductase (complex I) in the heart.
11 was also identified as a negative regulator of signal transducer and activator of transcription (Stat)3. 12, 13 To reveal its physiological role, we generated GRIM-19-deficient mice by gene targeting. 14 Although the deletion of GRIM-19 causes embryonic lethality, isolated À/À blastocysts displayed abnormal mitochondrial structure and morphology. Consistent with this finding, we further demonstrated that GRIM-19 is localized in the mitochondria, associates with mitochondrial complex I, and plays essential roles in the assembly and enzymatic activity of complex I. 14 Based on its primary function in mitochondria, GRIM-19 has been recently suggested to be re-named as NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 13 (NDUFA13) by HUGO Gene Nomenclature Committee (HGNC).
Mitochondria play many roles in cells. They generate ATP by oxidative phosphorylation (OXPHOS) via the mitochondrial respiratory chain (MRC) consisting of five multisubunit complexes (complexes I-V), which are encoded either by mitochondrial or nuclear DNA. [15] [16] [17] [18] Mitochondria also play a pivotal role in apoptosis induced by a variety of extra-and intracellular stresses that leads to the release of potentially toxic proteins, such as cytochrome c, and subsequent caspase activation. 19 To what extent its functions in 'life' and 'death' are related is still unclear. The finding that GRIM-19 is a complex I subunit raises a question of whether complex I, or the whole MRC in general, is involved and required for IFN/RA-induced cancer cell death. Our studies reported here indicate that IFN/RA-triggered cell death depends on the MRC, and therefore links normal MRC function to the apoptosis induced by IFN/RA treatment.
Results
IFN-b/RA upregulates expression of various MRC subunits. Complex I is the largest complex in the MRC containing at least 46 subunits. 20, 21 It has been shown previously that IFN-b/RA treatment increases the mRNA level of GRIM-19 in human breast carcinoma cell lines. 10 In this study, we investigated whether IFN-b/RA treatment can also stimulate expression of other MRC subunits in these cancer cell lines. We chose certain subunits encoded by the nucleus from complex I-V based on the antibody availability. Figure 1a shows that three subunits of complex I (GRIM-19, NDUFS3, and NDUFS5) were upregulated strongly and two (NUDFB6 and NDUFA9) increased slightly after treatment with IFN-b/RA in MCF-7 cells. In addition, expression of subunits UQCRFS1, an iron-sulfur protein from complex III, COX II and COX IV from complex IV, and ATPI from complex V were also elevated by IFN-b/RA. In contrast, SDHA, a flavoprotein from complex II, which exhibited relatively high expression in the untreated cells, was not obviously enhanced after the treatment. A similar expression pattern of these individual subunits was also observed in HeLa cells. More importantly, the synergistic upregulation of these subunits was dependent on the combination of IFN-b and RA, as IFN-b or RA alone had no inducing effect in most cases ( Figure 1b) . As controls, tubulin and actin were unchanged upon stimulation. These results indicate that the combination of IFN-b and RA synergistically upregulates the expression of certain subunits of MRC complexes I, III, IV, and V in the cancer cell lines.
To test whether the MRC subunits are upregulated at the transcriptional level, we performed real-time RT-PCR to quantify the mRNA amount of both GRIM-19 and NDUFS3 at different time points after the initiation of IFN-b/RA stimulation. The results showed that their mRNA levels also increased by the treatment (Figure 1c ).
IFN-b/RA induces cell death via a mitochondrialmediated pathway. Next, the effects of IFN/RA on cell growth and death were examined. IFN-b or RA alone reduced the cell number slightly (o15%), whereas a combination of the two drugs resulted in a drastic decrease Synergistic induction of complex subunits by a combination of IFN-b and RA. HeLa cells were untreated or treated with different doses of IFN-b (U/ml) and 1 mM of RA as indicated for 5 days. Cells were harvested and the complex subunits were analyzed as described above. (c) GRIM-19 and NDUFS3 were upregulated at the transcriptional level. HeLa cells were treated as in (a). RNA was extracted at different time points as indicated. mRNA levels of GRIM-19 and NDUFS3 were quantified by real-time RT-PCR using GAPDH as an internal control in the cell numbers (480%) (Figure 2a ). Both propidium iodide (PI) (Figure 2b ) and Annexin V (Figure 2c ) staining showed obvious cell death from day 3 after IFN-b/RA treatment, and more than 60% of total cells undergoing apoptosis at day 5. Known cell death pathways are mediated by either death receptors or via mitochondria. In the mitochondrial-mediated death pathway, the apoptotic signals lead to opening of the mitochondrial permeability transition pore that induces loss of the transmembrane potential (DC m ), release of cytochrome c, and activation of caspases. 19 To further explore which apoptotic pathway that IFN-b/RA triggers in cells, we checked these apoptotic events. First, we observed that the cell number with low DC m increased from day 3, and reached B50% at day 5 ( Figure 2d ). Then, cytochrome c release and caspase activation were analyzed by Western blotting. A very low level of cytochrome c released into the cytoplasm was detected at day 1, which reached and remained at a high level from days 3 to 5 ( Figure 2f ). Following cytochrome c release, caspase-9 was cleaved and activated. A 10-kDa cleaved fragment increased from days 1 to 3, and further decreased at day 4, possibly by further cleavage. Activation of caspase-9 led to cleavage of procaspase-3 and resulted in the release of both 19-kDa and 17-kDa fragments of caspase-3, which were detected from day 2, and enhanced from days 3 to 5. Two cellular caspase-3 substrates, poly(ADP-ribose) polymerase (PARP) and a-fodrin, were cleaved upon activation of caspase-3, yielding an 85-kDa and a 120-kDa fragment, respectively, from day 2. These cleaved products further increased from day 2 onwards with very strong expression at day 5 for PARP, and days 4 and 5 for a-fodrin. On the other hand, activation of caspase-8 to IFN-b/RA does not cause specific cytoplasmic or nuclear translocation of the MRC complex subunits. Apoptosisinducing factor (AIF) is a flavoprotein with NADH oxidase activity normally residing in the mitochondrial inner membrane space. Upon apoptosis induction, AIF translocates from mitochondria to the cytosol, and subsequently to the nucleus. 22 We investigated whether GRIM-19 and other MRC subunit proteins also underwent translocation similar to AIF. As shown in Figure 3 (left panels), GRIM-19 and NDUFS5 (complex I subunits), SDHA (a complex II subunit), COX II (a complex IV subunit), ATP1 (a complex V subunit), and cytochrome c were all located in the mitochondria as observed by colocalization with MitoTracker Red in the untreated cells. After IFN-b/RA treatment for 4 days, many cells displayed apoptotic features such as nuclear condensation. Even in these cells, the majority of the proteins tested were still located in the mitochondria, except for cytochrome c, which was released into the cytosol ( Figure 3 , right panels). In the cells with normal nuclear morphology after IFN-b/RA treatment for less than 4 days, the complex subunits were all localized inside the mitochondria similar to those in the untreated cells (data not shown). These data indicate the absence of nuclear translocation of MRC complex subunits, including GRIM-19, during IFN/RA-induced cell death.
Knockdown of NDUFS3 and GRIM-19 protects cells against IFN-b/RA-induced apoptosis. To further investigate whether MRC is necessary for IFN-b/RA-induced apoptosis, we knocked down the complex I subunits, GRIM-19 and NDUFS3, in MCF-7 and HeLa cells using siRNA. efficiency of GRIM-19 and NDUFS3 was further evaluated by their effects on complex I enzymatic activity using a blue native polyacrylamide gel electrophoresis (BN-PAGE) assay. Mitochondria were isolated from cells and the complexes I-V were separated by BN-PAGE. The activity of complex I was analyzed in gel as described previously. 14 In comparison with the WT and the control SC cells, complex I activity was significantly reduced in G19 and almost undetectable in p30 cells (Figure 4b ). Interestingly, we observed a slow growth after 2 days of treatment and a cell death at days 4 and 6 in the WT Three independent experiments were performed and the results were similar. (e) and (f) WT, SC, G19, and p30 cells were treated as same as in (c) and the cell death was analyzed by staining with Annexin V (e) or active caspase-3 (f) as described in Figure 2 . (g) Analyses of cytochrome c release and caspase activation induced by IFN-b/RA in SC and p30 cell lines were performed as same as described in Figure 2f and SC cells. However, G19 and p30 cells showed more cell growth after 2 days, which was sustained at days 4 and 6 with much less apoptosis (Figure 4c and d) .
The antiapoptotic effect of GRIM-19 and NDUFS3 knockdown was further confirmed. In contrast to WT and SC cells, the death of G19 and p30 cells was decreased after treatment for 2 days and reduced to 40% as detected by Annexin V staining (Figure 4e ). Correspondingly, these cells also showed much lower amounts of active caspase-3 ( Figure 4f ). In agreement with these results, no increases of cytochrome c release and PARP (85 kDa) and a-fodrin (120-kDa) cleavage above the basal level were observed in p30 cells after IFN-b/RA treatment for up to 5 days in comparison with control cells (SC) (Figure 4g ). Taken together, there results demonstrate that suppression of complex I activity by knocking down GRIM-19 or NDUFS3 subunit confers cell resistance to IFN-b/RA-induced apoptosis.
IFN-b/RA treatment promotes mitochondrial generation of ROS. It has been documented that electron transport through the MRC is accompanied by the generation of various kinds of free radicals. 23, 24 Overproduction of reactive oxygen species (ROS), the by-product of the MRC, causes cell death. 25 We examined whether overproduction of ROS by upregulation of MRC results in apoptosis upon treatment with IFN-b/RA. As shown in Figure 5a , IFN-b/RA treatment led to the cell population with high ROS increased from 10% in the untreated cells to near 60% in the cells treated for 5 days. However, G19 and p30 cells had fewer cells with a high ROS production after treatment (Figure 5b ). We next tested whether overproduction of ROS contributed to cell death by using ROS scavengers, pyrrolidinedithiocarbamate (PDTC), allopurinol, and superoxide dismutase (SOD). As these ROS scavengers had nonspecific toxicity to the cells with prolonged incubation and ROS was mainly produced after day 3, we added these drugs at day 2 after IFN-b/RA treatment. As shown in Figure 5c . 26 RA was reported to potentiate the effect of IFN by upregulating Stat1, Stat2, and p48. RA itself can also induce expression of some ISGs, such as IRF-1, which can induce expression of more ISGs.
27,28 IRF-1, as a tumor suppressor with antiproliferative function, can also induce expression of the death ligand TNF-related apoptosisinducing ligand (TRAIL) in cancer cells treated with RA and IFN-g. 29 In addition, both IFN-a and RA are able to increase the expression of tissue transglutaminase II (tTGase II), a multifunctional enzyme with an apoptotic role in various cells. [30] [31] [32] To investigate the IFN-b/RA signaling pathway in MCF-7 cells, we tested tyrosine phosphorylation of Stat1 and gene expression of the key players described above. As shown in Figure 6a , tyrosine phosphorylation of Stat1 can be detected as early as 5 min after stimulation, which reached a peak level at 30 min and decreased after 3 h. The Stat1 protein level was rather constant during the early time course, but increased gradually after treatment from 9 to 48 h. IRF-1 expression was induced from 3 to 12 h, whereas p48 expression increased at 6 h and was further enhanced at 48 h. In contrast, Stat2 and TRAIL, and tissue tTGase II expression increased at a much later time (48 and 24 h, respectively). These genes, therefore, can be classified as late signaling response genes to the IFN-b/RA stimulation.
Next, we examined these responses to the IFN-b/RA stimulation in the NDUFS3 (p30) and GRIM-19 (G19) knockdown cells. As shown in Figure 6b , there is no difference in the tyrosine phosphorylation of Stat1 and induction of IRF-1 and p48 among p30, G19, and control SC cells. However, the amounts of Stat2 and tTGase II induced by IFN-b/RA in G19 and p30 cells were reduced, which was more significant in p30 than G19 cells. Furthermore, a decrease of TRAIL in p30 was detected, even in the untreated cells. These results are consistent to the observation of a higher inhibitory efficiency of complex I activity in p30 than G19 cells (Figure 4b ). These data suggest that late rather than early responses in the IFN-b/RA-induced signaling and gene expression depends on complex I activity.
To exclude the possibility that the late genes are induced as a consequence rather than a cause of apoptosis, we tested protein levels of these genes in response to IFN-b/RA in the presence of either a pancaspase inhibitor (z-VAD-fmk) or a caspase-3-specific inhibitor (z-DEVD-fmk). No inducible B17-kDa cleavage products of caspase-3 were detected when the cells were treated with either z-VAD-fmk or z-DEVDfmk. Stat2 and tTGaseII was still upregulated in the presence of the caspase inhibitors. Furthermore, upregulation of GRIM-19 and NDUFS3 by IFN/RA was not inhibited by the caspase inhibitors (Figure 6c and 6d ). These results demonstrate that induction of the MRC proteins and the late gene expression by IFN/RA is not the consequence of cell death.
As IFN-b/RA leads to an increase in ROS production, we also explored the possibility that ROS production was required for the regulation of IFN-b/RA-responsive genes. The results showed that pretreatment of the normal cells with ROS scavengers before IFN-b/RA did not inhibit Stat1 tyrosine phosphorylation and the upregulation of IRF-1, p48, Stat2, and tTGase II (Supplementary Figure 1) . This experiment suggests that the late signaling induced by IFN-b/RA is likely to be independent of ROS production.
The role of the MRC in cell death is specific for IFN-b/RA treatment. We also tested the effects of the MRC on cell death induced by generic apoptotic agents. We observed that treatment of HeLa cells with UV irradiation, camptothecin (CPT), or staurosporine (STS) triggered apoptosis by increasing cytochrome c release and cleavage of PARP and a-fodrin in both control SC and the GRIM-19 or NDUFS3 knockdown cells. Consistently, the expression levels of GRIM-19 and NDUFS3 were not elevated by these treatments (Supplementary Figure 2a-c) . Furthermore, cell death indicated by cell morphology, Annexin V staining, and DC m induced by these agents was similar regardless of whether or not GRIM-19 and NDUFS3 were knocked down ( Supplementary Figure 2d-f) . These results indicate a specific involvement of the MRC in IFN-b/RA-induced cell death.
A model of IFN-b/RA-induced cell death. IFN-b/RAinduced apoptosis is a prolonged process that involves complex regulatory events. Based on our data presented above, we propose a model for IFN-b/RA-induced cell death with a central role for the MRC (Figure 7) . IFN-b/RA stimulation induces activation of signal molecules and primary gene expression. These early responses promote MRC activity by upregulation of its complexes. Increased MRC activity, in turn, promotes more ROS production, which triggers mitochondrial-mediated apoptosis pathways. In parallel, MRC activation amplifies IFN-b/RA-induced signaling by upregulating expression of late response genes, either antiproliferative or proapoptotic, which also leads to cell growth inhibition and apoptosis.
Discussion
A synergistic anticancer action by combination of RA with IFNs is extensively analyzed both in vitro and in clinical trials. 8, 9 The discovery of GRIM-19 as an IFN-b/RA-inducible gene product 10 role of MRC in cell death seems specific only for the combination of IFN-b and RA, as IFN or RA alone did not induce either upregulation of the MRC subunits or the cell death (Figures 1 and 2) . Furthermore, other death stimuli such as UV, CPT, and staurosporine caused cell death without inducing the expression of GRIM-19 and NDUFS3, and knockdown of these two genes did not prevent cell death induced by these generic death agents (Supplementary Figure 2) . Therefore, MRC plays a specific role in IFN-b/RAinducible cancer cell death.
The mechanism of how upregulation of the MRC leads to cell death is not fully understood. We have provided evidence that overproduction of ROS and upregulation of late gene expression necessary for cell death may be two major reasons. It has been reported that the transcription factor nuclear factor-kB (NF-kB) can be upregulated in response to various oxidative stress stimuli. 33 However, inhibition of ROS generation did not suppress the upregulation of the IFN-b/RAresponsive genes (Supplementary Figure 1) . Therefore, it is unlikely that IFN-b/RA triggers gene expression via ROS production. Other mechanisms such as nuclear translocation were also investigated. GRIM-19 was originally claimed as a nuclear protein, 10 but was later shown to be a mitochondrial protein. 11, 12, 14 In a recent review by Kalvakolanu, 34 it was proposed that GRIM-19 may initiate apoptosis, like cytochrome c and AIF, by translocation from the mitochondria to the nucleus upon IFN-b/RA stimulation. To test this hypothesis, we analyzed the cellular localization of GRIM-19, as well as other MRC subunit proteins, in the absence and presence of IFN-b/RA. We showed that without induction, these proteins colocalized with MitoTracker Red and displayed a typical mitochondrial localization pattern. IFN-b/RA treatment resulted in varying levels of apoptosis. However, nuclear translocation of GRIM-19 or other MRC subunits tested was not found in both nonapoptotic and apoptotic cells. As a control, cytochrome c was translocated into the cytoplasm after treatment (Figure 3) . These results demonstrate that the MRC does not exert its regulatory role in IFN-b/ RA-induced cell death via direct nuclear translocation. Our data also show that the regulation and function of GRIM-19 are very similar to NDUFS3, another complex I subunit. This supports that GRIM-19 is a subunit of the MRC complex I, but not a nuclear protein with a nuclear function in IFN-b/RAtriggered cancer cell death. Our data therefore clarify the confusion in the field about the identity and cellular localization of GRIM-19.
The function of the MRC complex I activity in protecting cells against IFN-b/RA-induced apoptosis is demonstrated by knockdown of GRIM-19 and NDUFS3 in MCF-7 and HeLa cells (Figures 4-6) . The effects of the other MRC complexes were also investigated by using the inhibitors rotenone, 2-thenoyltrifluoroacetone (TTFA), antimycin A, and oligomycin, for inhibition of complexes I, II, III, and V, respectively. As prolonged inhibition by these drugs at the optimal doses that completely inhibits complex activity killed cells even in the absence of IFN-b/RA, suboptimal doses of each inhibitor that did not cause cell death were used. Although rotenone, TTFA, and oligomycin exhibited partial rescue for IFN-b/RA-induced cell death, the inhibitory effects of these drugs at the suboptimal doses used in these experiments on complex activities remains unknown (data not shown). Therefore, a clear conclusion for this could not be drawn currently.
Mitochondria have both life-supporting functions and deathpromoting activities. However, studies attempting to address the question of whether these two crucial cellular processes are linked to each other have resulted in controversial conclusions. 15 Early evidence showed that cultured cells lacking mitochondrial DNA and therefore deficient in respiration could undergo apoptosis, suggesting that MRC is not necessary for apoptosis. 35, 36 Recent evidence, however, also indicates that the physiological functions of mitochondria are involved in cell death. 15 As examples, reports show that a functional electron transport chain regulates oxygen deprivation-induced cell death, and an ATP synthase is required in TNF-induced apoptosis. [37] [38] [39] In this study, using a lossof-function approach, we demonstrated that the function of complex I is necessary for IFN/RA-induced cancer cell death, suggesting that changes in cellular metabolism can directly affect the sensitivity of a cell to apoptosis induced by specific agents. Our data provide another example where mitochondrial physiology plays a direct role in apoptotic cell death.
Materials and Methods
Cell culture, chemicals, and reagents. HeLa cells were maintained in Eagle's minimum essential medium (MEM) (Sigma, St Louis, IL, USA) supplemented with 10% fetal bovine serum (FBS). When HeLa were treated with INF-b and RA, 5% charcoal-stripped FBS was used. MCF-7 cells were maintained in RPMI-1640 medium (Sigma) supplemented with 10% FBS. During treatment with IFN-b and RA, MCF-7 cells were cultured in phenol red-free MEM (Sigma) supplemented with 5% charcoal-stripped FBS and 10 À11 M estradiol. RA, PI, PDTC, allopurinol, and SOD were purchased from Sigma. TMRE, dihydroethidium (2-HE) and MitoTracker Red CMXRos were from Molecular Probes (Eugene, OR, USA). z-DEVD-fmk and z-VAD-fmk were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA) and Calbiochem (Darmstadt, Germany), respectively. Antibodies against NDUFS5, NDUFB6, NDUFS3, NDUFA9, SDHA, UQCRFS1, COX II, COX IV, and ATPI were from Molecular Probes. b-Tubulin, active caspase-9, p48, TRAIL, and tTGase II antibodies were from Santa Cruz Biotechnology. Antiactin antibody was from Sigma. IRF-1 and Stat2 antibodies were from BD Transduction Laboratories (Lexington, KY, USA). Cytochrome c, caspase-8, and PARP antibodies were from BD Pharmingen (San Diego, CA, USA). Antibody against a-fodrin was from Chemicon (Temecula, CA, USA). Stat1-pY701 antibody was from Cell Signalling (Danvers, MA, USA). GRIM-19 antibody was made as described.
14 Western blot analysis. Cells were harvested and washed with cold phosphate-buffered saline (PBS) and lysed in RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.2, 1% deoxycholic acid, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 0.25 mM EDTA) with the protease inhibitor cocktail (Roche, Basel, Switzerland). The lysate was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) after being boiled in Laemmli buffer, and transferred to polyvinylidene difluoride (PVDF) membrane. The membrane was blocked with PBS containing 0.1% Tween 20 and 1% bovine serum albumin before it was incubated with the appropriate primary and secondary antibodies. The bound antibodies were visualized by enhanced chemiluminescene (Amersham Bioscience, UK).
Cell growth assay. Cells were seeded in 60 mm dish at 2.6 Â 10 5 per dish and allowed to grow for 24 h before stimulation by IFN-b/RA for various times. Cells were washed with PBS and fixed with 70% ethanol at 41C for at least 1 h and stained with 4 0 ,6-diamidino-2-phenylindole (DAPI). Pictures were taken at randomly selected fields under a fluorescence microscope. Healthy cells were counted from each field and an average of five fields was taken as viable cell number. As a control, one plate was fixed before stimulation, and cell number obtained from this plate was taken as 0% growth. The cell number obtained from a plate of untreated cells at the end of the experiment was subtracted by the cell number at 0% growth and this was referred to as 100% growth. Cell number from the plate treated with IFN-b/RA was counted in a similar manner and the percentage of growth was plotted with reference to the untreated control. Each experiment was repeated at least three times and the results were comparable.
Measurement of DW m , ROS and apoptosis. Cells were treated as indicated, harvested and washed in PBS. For assessment of DC m and ROS, cells were resuspended in buffer A (20 mM Hepes-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM sodium EGTA, 1 mM dithiothreitol and 250 mM sucrose) and incubated with 50 nM of TMRE for DC m and 2 mM of 2-HE for ROS for 30 min at 371C in the dark. For cell death analysis, cells were washed and resuspended in PBS after treatment. PI (0.5 mg/ml) was then added. Assays were performed by flow cytometry. A commercial kit for Annexin V staining from BD Pharmingen was also used for death assay. Annexin V was measured in FL-1 (green), TMRE and 2-HE in FL-2 (red), and PI in FL-3 (far red).
Cytochrome c release assay. It was performed with a single-step protocol as described previously. 40 Briefly, HeLa cells were lysed for 15 min on ice in a solution consisting of 20 mM Hepes, pH 7.2, 50 mM KCl, 5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 250 mM sucrose, 0.025% digitonin, and protease inhibitor cocktail (Roche). After removal of the cell debris by centrifugation at 13 200 r.p.m. for 10 min at 41C, 10 mg of cell lysate was subjected to Western blot analysis using an antibody against cytochrome c.
Immunostaining. MCF-7 cells grown on glass coverslips in culture medium were first treated with 500 nM of MitoTracker Red CMXRos for 45 min before being fixed in 3.7% formaldehyde in PBS, permeabilized with 0.2% Triton X-100 in PBS, and blocked with FDB (5% normal goat serum, 2% FBS, and 2% bovine serum albumin in PBS). The cellular localization of complex subunits was detected using the respective primary monoclonal antibodies and an anti-mouse secondary antibody conjugated to fluorescein isothiocyanate (FITC). The cells were mounted in GEL MOUNTt (Biomeda Corp., Foster City, CA, USA) and examined under a fluorescent microscope (Leica DM4000 B Wetzlar, Germany). Images were collected and processed with a Leica DFC300 FX camera and Leica FW4000 software.
siRNA. Knockdowns by siRNA were performed using pSUPER.neo Mitochondrial complex I OXPHOS assays. Mitochondria were isolated according to a protocol as described previously.
14 Mitochondrial proteins were solubilized in 40 ml of solution containing 750 mM 6-aminocarproic acid, 50 mM Bistris (pH 7.0), and 5 ml of 10% dodecylmaltoside. The lysate was centrifuged and the supernatant was used for further assays. The separation of mitochondrial complexes was performed on 5-18% polyacrylamide gradient BN-PAGE. In-gel colorimetric reaction for OXPHOS of complex I was performed on the BN-PAGE as described previously.
14 Briefly, following BN-PAGE, the gels were rinsed with distilled water and then equilibrated in complex I reaction buffer (0.1 M Tris-HCl, pH 7.4) for 10 min. The gels were subsequently incubated for 30 min in fresh complex I reaction buffer containing 0.2 mM NADH and 0.2% nitroblue tetrazolium (NBT) as substrates. The gels were then destained overnight in 45% methanol and 10% acetic acid.
Quantitative RT-PCR. RNA was isolated by TRIzol reagent (Invitrogen). Firststrand synthesis was carried out using a poly(dT) primer and Superscript II Reverse Transcriptase (Invitrogen). Real-time PCR was performed on a Roche Light Cycler using the Light Cycler FastStart DNA master SYBR Green I kit (Roche). Quantification was carried out by normalizing levels to the amount of total cDNA using the ubiquitously expressed GAPDH as a standard. The primers used are 5 0 -ATGGGCCCATCGACTACAAAC-3 0 (forward) and 5 0 -GAAGCCGTGGCT GGCA TGGA-3 0 (reverse) for GRIM-19; 5 0 -CACGCGCCCCACTGTCA-3 0 (forward) and 5 0 -CACCCGCTTCACTTCATCATCATA-3 0 (reverse) for NDUFS3; and 5 0 -TCCATCA CCATCTTCCAG -3 0 (forward) and 5 0 -ATGAGTCCTTCCACGATACC-3 0 (reverse) for GAPDH.
Flow cytometric analysis of caspase-3 activation. Upon induction of apoptosis, caspase-3 undergoes conformational changes that exposes otherwise inaccessible epitopes. By staining the cells with antiactivated caspase-3 (Cell Signaling) and an FITC-conjugated secondary antibody, increases in accessibility of the epitopes can be monitored by flow cytometry. At specific time points following IFN-b/RA treatment, the cells were harvested, fixed with 2% formaldehyde, and permeabilized with ice-cold 90% methanol. After staining with primary and secondary antibodies, cells were analyzed by flow cytometer in FL-1 (green).
